RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: Parasitic Skin Diseases
Accession: DOID:9007630
browse the term
Definition: Skin diseases caused by ARTHROPODS; HELMINTHS; or other parasites.
Synonyms: exact_synonym: Parasitic Skin Disease; parasitic skin disorder
primary_id: MESH:D012876
G
CAT
catalase
ISO
protein:decreased activity:erythrocyte:
RGD
PMID:9892499
RGD:9479188
NCBI chr11:34,413,253...34,446,831
Ensembl chr11:34,289,603...34,323,160
G
CCL2
C-C motif chemokine ligand 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:20102417
NCBI chr17:22,528,154...22,530,091
Ensembl chr17:22,820,890...22,823,384
G
CCR1
C-C motif chemokine receptor 1
ISO
RGD
PMID:12874303
RGD:5688168
NCBI chr 3:46,107,526...46,114,229
Ensembl chr 3:47,214,688...47,215,755
G
CCR2
C-C motif chemokine receptor 2
ISO
mRNA:increased expression:foot, lymph node
RGD
PMID:12874303
RGD:5688168
NCBI chr 3:46,255,725...46,263,285
Ensembl chr 3:47,361,124...47,368,312
G
CCR5
C-C motif chemokine receptor 5
no_association
ISO
DNA:frameshift mutation: :p.S185_T195del (rs333) (human)
RGD
PMID:17214851 PMID:23632983
RGD:8549764 RGD:8549765
NCBI chr 3:46,273,096...46,278,471
Ensembl chr 3:47,380,321...47,381,379
G
CD163
CD163 molecule
ISO
mRNA, protein:increased expression:skin of body, blood plasma, CD14-positive monocyte (human)
RGD
PMID:32023254
RGD:127345130
NCBI chr12:7,616,714...7,649,768
Ensembl chr12:7,775,343...7,810,023
G
CD274
CD274 molecule
ISO
RGD
PMID:16358363
RGD:41410801
NCBI chr 9:5,269,270...5,289,629
Ensembl chr 9:5,454,391...5,474,402
G
COL1A1
collagen type I alpha 1 chain
ISO
DNA:SNPs: :rs1061237, rs2586488 (human)
RGD
PMID:25562121
RGD:11041176
NCBI chr17:44,274,349...44,291,764
Ensembl chr17:49,150,677...49,166,677
G
CXCL8
C-X-C motif chemokine ligand 8
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:20102417
NCBI chr 4:50,452,857...50,456,015
Ensembl chr 4:56,286,708...56,288,083
G
FOXP3
forkhead box P3
ISO
mRNA:increased expression:Peripheral blood mononuclear cell:
RGD
PMID:29205403
RGD:38455981
NCBI chr X:41,550,462...41,567,492
Ensembl chr X:49,402,652...49,417,029
G
IFNG
interferon gamma
treatment
ISO
CTD Direct Evidence: marker/mechanism|therapeutic
CTD RGD
PMID:8154019 PMID:9234779 PMID:20102417 PMID:27999013
RGD:40890273
NCBI chr12:65,663,764...65,668,732
Ensembl chr12:68,448,861...68,453,829
G
IL10
interleukin 10
ISO
CTD Direct Evidence: marker/mechanism mRNA:increased expression:Peripheral blood mononuclear cell:
CTD RGD
PMID:20102417 PMID:29205403
RGD:38455981
NCBI chr 1:182,369,234...182,374,207
Ensembl chr 1:186,648,289...186,653,371
G
IL13
interleukin 13
treatment
ISO
RGD
PMID:12739821 PMID:18924210
RGD:8549536 RGD:8549561
NCBI chr 5:128,073,863...128,078,453
Ensembl chr 5:134,235,788...134,240,548
G
IL17A
interleukin 17A
ISO
mRNA:increased expression:Peripheral blood mononuclear cell:
RGD
PMID:29205403
RGD:38455981
NCBI chr 6:51,736,269...51,740,538
Ensembl chr 6:53,004,820...53,009,074
G
IL1B
interleukin 1 beta
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:20102417
NCBI chr2A:89,216,313...89,223,358
Ensembl chr2A:113,846,306...113,853,424
G
IL23A
interleukin 23 subunit alpha
ISO
RGD
PMID:29078003
RGD:39457938
NCBI chr12:32,575,321...32,576,856
Ensembl chr12:32,828,902...32,830,617
G
IL32
interleukin 32
susceptibility ameliorates
ISO
DNA:SNPs:enhancers: (rs4786370, rs4349147) (human)
RGD
PMID:28709468 PMID:32023240
RGD:150340717 RGD:150340742
NCBI chr16:2,007,018...2,023,757
Ensembl chr16:3,179,637...3,203,929
G
IL4
interleukin 4
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:20102417
NCBI chr 5:128,091,342...128,099,886
Ensembl chr 5:134,253,039...134,261,581
G
LTA
lymphotoxin alpha
no_association
ISO
DNA:SNP:intron:252A>G (human)
RGD
PMID:16950634
RGD:8548800
NCBI chr 6:31,233,411...31,235,409
Ensembl chr 6:32,123,353...32,125,375
G
LTB
lymphotoxin beta
ISO
RGD
PMID:17911622
RGD:8548820
NCBI chr 6:31,241,643...31,244,454
Ensembl chr 6:32,131,760...32,133,467
G
MMP2
matrix metallopeptidase 2
treatment
ISO
CTD Direct Evidence: marker/mechanism
RGD CTD
PMID:21091666
RGD:8657030
NCBI chr16:35,711,866...35,738,881
Ensembl chr16:54,812,694...54,844,279
G
PDCD1LG2
programmed cell death 1 ligand 2
ISO
RGD
PMID:16358363
RGD:41410801
NCBI chr 9:5,313,071...5,391,676
Ensembl chr 9:5,514,449...5,575,688
G
PIK3CD
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
treatment
ISO
RGD
PMID:27999013
RGD:40890273
NCBI chr 1:8,418,570...8,495,435
Ensembl chr 1:9,686,208...9,724,633
G
SLC11A1
solute carrier family 11 member 1
ISO
DNA:insertion/deletion (human)
RGD
PMID:20089160
RGD:5684930
NCBI chr2B:105,640,613...105,655,524
Ensembl chr2B:224,238,284...224,252,941
G
SOD1
superoxide dismutase 1
ISO
protein:increased activity:erythrocyte:
RGD
PMID:9892499
RGD:9479188
NCBI chr21:18,029,831...18,037,526
G
STAT4
signal transducer and activator of transcription 4
ISO
RGD
PMID:10458767
RGD:8661703
NCBI chr2B:78,331,402...78,549,231
Ensembl chr2B:196,247,881...196,366,011
G
TLR2
toll like receptor 2
ISO
protein:decreased expression:skin:
RGD
PMID:20493664
RGD:7794748
NCBI chr 4:146,024,653...146,091,388
Ensembl chr 4:157,866,977...157,869,331
G
TLR4
toll like receptor 4
ISO
protein:decreased expression:skin:
RGD
PMID:20493664
RGD:7794748
NCBI chr 9:88,827,495...88,840,458
Ensembl chr 9:117,180,550...117,190,711
G
TNF
tumor necrosis factor
no_association
ISO
CTD Direct Evidence: marker/mechanism DNA:SNP:promoter:-308G>A (rs1800629) (human)
CTD RGD
PMID:16950634 PMID:20102417
RGD:8548800
NCBI chr 6:31,236,650...31,239,423
Ensembl chr 6:32,126,618...32,129,381
G
AGER
advanced glycosylation end-product specific receptor
ISO
protein:increased expression:brain
RGD
PMID:25014011
RGD:8695986
NCBI chr 6:31,828,363...31,831,981
Ensembl chr 6:32,708,251...32,711,641
G
ARG1
arginase 1
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:21232540
NCBI chr 6:129,372,747...129,383,880
Ensembl chr 6:133,479,966...133,491,162
G
BTK
Bruton tyrosine kinase
susceptibility
ISO
RGD
PMID:28783468
RGD:124715477
NCBI chr X:90,551,874...90,588,786
Ensembl chr X:100,684,017...100,725,187
G
C3
complement C3
ISO
RGD
PMID:15378355
RGD:7401274
NCBI chr19:5,708,211...5,753,178
Ensembl chr19:6,629,287...6,674,699
G
CCR2
C-C motif chemokine receptor 2
ISO
RGD
PMID:10899907
RGD:8661227
NCBI chr 3:46,255,725...46,263,285
Ensembl chr 3:47,361,124...47,368,312
G
CCR5
C-C motif chemokine receptor 5
disease_progression
ISO
associated with HIV Infections;protein:increased expression:blood, T cell
RGD
PMID:10553079 PMID:17457607
RGD:8551832 RGD:8551841
NCBI chr 3:46,273,096...46,278,471
Ensembl chr 3:47,380,321...47,381,379
G
CRP
C-reactive protein
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:17218153
NCBI chr 1:135,062,102...135,064,402
G
DUSP1
dual specificity phosphatase 1
treatment
ISO
RGD
PMID:21471446
RGD:7771536
NCBI chr 5:168,121,536...168,124,671
Ensembl chr 5:175,032,803...175,035,960
G
DUSP6
dual specificity phosphatase 6
treatment
ISO
RGD
PMID:21471446
RGD:7771536
NCBI chr12:86,875,289...86,879,731
Ensembl chr12:90,195,482...90,200,321
G
IFNG
interferon gamma
ISO
CTD Direct Evidence: marker/mechanism
RGD CTD
PMID:2145107 PMID:16540374 PMID:17218153
RGD:7829781
NCBI chr12:65,663,764...65,668,732
Ensembl chr12:68,448,861...68,453,829
G
IL10
interleukin 10
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:16540374 PMID:20404924
NCBI chr 1:182,369,234...182,374,207
Ensembl chr 1:186,648,289...186,653,371
G
IL18
interleukin 18
treatment
ISO
CTD Direct Evidence: marker/mechanism
RGD CTD
PMID:10768930 PMID:16879623
RGD:8655909
NCBI chr11:107,024,376...107,045,194
Ensembl chr11:110,867,586...110,888,371
G
IL2
interleukin 2
ISO
RGD
PMID:6224858
RGD:8693326
NCBI chr 4:114,637,328...114,642,586
Ensembl chr 4:125,782,563...125,787,984
G
IL21
interleukin 21
exacerbates
ISO
protein:increased expression:popliteal lymph node (mouse)
RGD
PMID:22429963
RGD:127285547
NCBI chr 4:114,795,979...114,806,936
Ensembl chr 4:125,943,495...125,951,915
G
IL27
interleukin 27
exacerbates
ISO
RGD
PMID:25466588
RGD:126790552
G
IL4
interleukin 4
treatment
ISO
protein:increased expression:serum
RGD
PMID:2145107 PMID:2521244
RGD:7829781 RGD:7829820
NCBI chr 5:128,091,342...128,099,886
Ensembl chr 5:134,253,039...134,261,581
G
IL6
interleukin 6
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:16540374
NCBI chr 7:23,415,922...23,420,767
G
ITGB2
integrin subunit beta 2
ameliorates
ISO
RGD
PMID:14502280
RGD:127285813
NCBI chr21:31,181,228...31,216,033
Ensembl chr21:44,470,999...44,505,963
G
MCL1
MCL1 apoptosis regulator, BCL2 family member
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:26670606
NCBI chr 1:125,918,760...125,923,952
Ensembl chr 1:129,566,827...129,572,086
G
SLC6A4
solute carrier family 6 member 4
ISO
lupoid leishmaniasis;protein:increased expression:skin of body (human)
RGD
PMID:23989888
RGD:36947873
NCBI chr17:26,546,177...26,572,301
Ensembl chr17:27,050,900...27,092,882
G
TNF
tumor necrosis factor
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:16540374
NCBI chr 6:31,236,650...31,239,423
Ensembl chr 6:32,126,618...32,129,381
G
TNFRSF18
TNF receptor superfamily member 18
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:20139272
G
TNFSF4
TNF superfamily member 4
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:10637281
NCBI chr 1:148,684,689...148,989,775
Ensembl chr 1:152,391,450...152,415,845 Ensembl chr 1:152,391,450...152,415,845
G
TREM1
triggering receptor expressed on myeloid cells 1
severity
ISO
RGD
PMID:24453980
RGD:126925972
NCBI chr 6:40,861,283...40,874,446
Ensembl chr 6:42,163,337...42,183,091
G
VDR
vitamin D receptor
ISO
RGD
PMID:17551101
RGD:8158083
NCBI chr12:40,828,413...40,891,700
Ensembl chr12:41,702,742...41,766,192
G
TLR2
toll like receptor 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:29253318
NCBI chr 4:146,024,653...146,091,388
Ensembl chr 4:157,866,977...157,869,331
G
IFNG
interferon gamma
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:7854095
NCBI chr12:65,663,764...65,668,732
Ensembl chr12:68,448,861...68,453,829
G
LTA
lymphotoxin alpha
ISO
DNA:polymorphism:intron
RGD
PMID:7595196
RGD:8548799
NCBI chr 6:31,233,411...31,235,409
Ensembl chr 6:32,123,353...32,125,375
G
TNF
tumor necrosis factor
ISO
DNA:SNP:promoter:-308G>A (human)
RGD
PMID:7595196
RGD:8548799
NCBI chr 6:31,236,650...31,239,423
Ensembl chr 6:32,126,618...32,129,381
G
IL1R1
interleukin 1 receptor type 1
ISO
RGD
PMID:19168746
RGD:8662882
Ensembl chr2A:103,193,131...103,230,005
G
TLR4
toll like receptor 4
ISO
RGD
PMID:11884755
RGD:7794682
NCBI chr 9:88,827,495...88,840,458
Ensembl chr 9:117,180,550...117,190,711
G
IL13
interleukin 13
severity
ISO
protein:increased expression:serum
RGD
PMID:22805723
RGD:8549600
NCBI chr 5:128,073,863...128,078,453
Ensembl chr 5:134,235,788...134,240,548
G
LOC100995577
HLA class II histocompatibility antigen, DP alpha 1 chain
ISO
RGD
PMID:8854084
RGD:6480649
NCBI chr 6:32,637,826...32,646,501
Ensembl chr 6:33,752,638...33,761,417
G
CAT
catalase
treatment
ISO
RGD
PMID:17884035
RGD:9479747
NCBI chr11:34,413,253...34,446,831
Ensembl chr11:34,289,603...34,323,160
G
IL18
interleukin 18
treatment
ISO
RGD
PMID:16129701
RGD:8655932
NCBI chr11:107,024,376...107,045,194
Ensembl chr11:110,867,586...110,888,371
G
IL5
interleukin 5
severity
ISO
RGD
PMID:9824515
RGD:11354934
NCBI chr 5:127,955,377...127,961,726
Ensembl chr 5:134,119,608...134,121,675
G
IL1A
interleukin 1 alpha
ISO
RGD
PMID:7835923
RGD:7794724
NCBI chr2A:89,273,482...89,284,421
Ensembl chr2A:113,784,854...113,795,801
G
IL4
interleukin 4
treatment
ISO
RGD
PMID:26732352
RGD:11534298
NCBI chr 5:128,091,342...128,099,886
Ensembl chr 5:134,253,039...134,261,581
G
OLIG2
oligodendrocyte transcription factor 2
ISO
RGD
PMID:25773181
RGD:40902825
NCBI chr21:19,387,860...19,391,291
G
AICDA
activation induced cytidine deaminase
ISO
mRNA:altered expression:Bcell,CD4Tcell
RGD
PMID:31001826
RGD:32716386
NCBI chr12:8,688,392...8,699,008
Ensembl chr12:8,904,273...8,913,917
G
CCR2
C-C motif chemokine receptor 2
ISO
associated with Malnutrition;mRNA:increased expression:lymph node,spleen:
RGD
PMID:24818662
RGD:8661728
NCBI chr 3:46,255,725...46,263,285
Ensembl chr 3:47,361,124...47,368,312
G
CCR3
C-C motif chemokine receptor 3
ISO
protein:increased expression:blood, T cell
RGD
PMID:15379987
RGD:6893393
NCBI chr 3:46,147,928...46,172,947
Ensembl chr 3:47,253,878...47,278,630
G
CCR5
C-C motif chemokine receptor 5
treatment
ISO
RGD
PMID:24617012
RGD:14401738
NCBI chr 3:46,273,096...46,278,471
Ensembl chr 3:47,380,321...47,381,379
G
CD163
CD163 molecule
exacerbates
ISO
protein:increased expression:blood serum (human)
RGD
PMID:28355218
RGD:127345133
NCBI chr12:7,616,714...7,649,768
Ensembl chr12:7,775,343...7,810,023
G
CD40
CD40 molecule
treatment
ISO
RGD
PMID:14573667
RGD:8547750
NCBI chr20:42,455,711...42,467,139
Ensembl chr20:43,541,619...43,552,994
G
CD40LG
CD40 ligand
ISO
RGD
PMID:14573667
RGD:8547750
NCBI chr X:125,776,138...125,788,820
Ensembl chr X:136,042,849...136,058,202
G
CRP
C-reactive protein
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:10467834
NCBI chr 1:135,062,102...135,064,402
G
CSF2
colony stimulating factor 2
treatment
ISO
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:8035028 PMID:17404324
RGD:10449527
NCBI chr 5:127,496,951...127,499,325
Ensembl chr 5:133,660,775...133,663,146
G
CXCL10
C-X-C motif chemokine ligand 10
ISO
mRNA:increased expression:liver
RGD
PMID:16239557
RGD:27095947
NCBI chr 4:48,182,355...48,184,733
Ensembl chr 4:54,020,204...54,022,606
G
CXCL8
C-X-C motif chemokine ligand 8
treatment susceptibility
ISO
CTD Direct Evidence: marker/mechanism DNA:SNP:promoter:g.-251A>T (human)
CTD RGD
PMID:22461696 PMID:25821028 PMID:32984951
RGD:150523789 RGD:150523791
NCBI chr 4:50,452,857...50,456,015
Ensembl chr 4:56,286,708...56,288,083
G
HMOX1
heme oxygenase 1
treatment
ISO
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:22461696 PMID:23729024
RGD:42724459
NCBI chr22:16,388,368...16,401,289
Ensembl chr22:34,230,825...34,244,063
G
IFNG
interferon gamma
treatment
ISO
CTD Direct Evidence: therapeutic
CTD RGD
PMID:1901333 PMID:3104456 PMID:7854095 PMID:27999013
RGD:40890273 RGD:8158041
NCBI chr12:65,663,764...65,668,732
Ensembl chr12:68,448,861...68,453,829
G
IL10
interleukin 10
ISO
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:15716043 PMID:17404324 PMID:22461696 PMID:29745990
RGD:14975172
NCBI chr 1:182,369,234...182,374,207
Ensembl chr 1:186,648,289...186,653,371
G
IL10RA
interleukin 10 receptor subunit alpha
ISO
CTD Direct Evidence: therapeutic
CTD
PMID:15716043
NCBI chr11:112,820,445...112,835,603
Ensembl chr11:116,752,619...116,767,771
G
IL18
interleukin 18
susceptibility
ISO
RGD
PMID:16879623
RGD:8655922
NCBI chr11:107,024,376...107,045,194
Ensembl chr11:110,867,586...110,888,371
G
IL1B
interleukin 1 beta
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:17404324
NCBI chr2A:89,216,313...89,223,358
Ensembl chr2A:113,846,306...113,853,424
G
IL27
interleukin 27
ISO
mRNA, protein:increased expression:spleen, liver (mouse)
RGD
PMID:27245409
RGD:126790520
G
IL2RB
interleukin 2 receptor subunit beta
susceptibility
ISO
DNA:polymorphisms:exon:8777, 8838(human)
RGD
PMID:17108990
RGD:42724466
NCBI chr22:18,039,469...18,069,952
Ensembl chr22:35,874,898...35,899,038
G
IL32
interleukin 32
ameliorates
ISO
human gene in a mouse model
RGD
PMID:29483288
RGD:150340719
NCBI chr16:2,007,018...2,023,757
Ensembl chr16:3,179,637...3,203,929
G
IL6
interleukin 6
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:7554475 PMID:17404324 PMID:22461696
NCBI chr 7:23,415,922...23,420,767
G
IRF5
interferon regulatory factor 5
ISO
protein:increased expression:CD4 T cell, nucleus
RGD
PMID:30067973 PMID:32038622
RGD:40924560 RGD:40924629
NCBI chr 7:120,889,752...120,902,096
Ensembl chr 7:133,415,170...133,426,356
G
LTA
lymphotoxin alpha
severity
ISO
DNA:polymorphisms
RGD
PMID:12438370 PMID:15579454
RGD:8548784 RGD:8548789
NCBI chr 6:31,233,411...31,235,409
Ensembl chr 6:32,123,353...32,125,375
G
LTB
lymphotoxin beta
ISO
RGD
PMID:12115620
RGD:8548822
NCBI chr 6:31,241,643...31,244,454
Ensembl chr 6:32,131,760...32,133,467
G
MBL2
mannose binding lectin 2
disease_progression susceptibility
ISO
DNA:polymorphism:promoter: DNA:SNPs,haplotype:promoter,exon: protein:increased expression:serum:
RGD
PMID:17357060 PMID:22995279 PMID:26297290
RGD:11522692 RGD:8693721 RGD:8693726
NCBI chr10:49,401,364...49,409,328
Ensembl chr10:51,527,758...51,543,432
G
NFE2L2
NFE2 like bZIP transcription factor 2
treatment
ISO
RGD
PMID:23729024
RGD:42724459
NCBI chr2B:64,509,446...64,544,600
Ensembl chr2B:182,214,116...182,248,085
G
PIK3CD
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
treatment
ISO
RGD
PMID:27999013
RGD:40890273
NCBI chr 1:8,418,570...8,495,435
Ensembl chr 1:9,686,208...9,724,633
G
SLC11A1
solute carrier family 11 member 1
ISO
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:16597321 PMID:17067929
RGD:5684944
NCBI chr2B:105,640,613...105,655,524
Ensembl chr2B:224,238,284...224,252,941
G
STAT4
signal transducer and activator of transcription 4
ISO
RGD
PMID:24242758
RGD:8661696
NCBI chr2B:78,331,402...78,549,231
Ensembl chr2B:196,247,881...196,366,011
G
TLR2
toll like receptor 2
disease_progression
ISO
RGD
PMID:23589575
RGD:15090808
NCBI chr 4:146,024,653...146,091,388
Ensembl chr 4:157,866,977...157,869,331
G
TNF
tumor necrosis factor
severity
ISO
DNA:polymorphisms CTD Direct Evidence: marker/mechanism
RGD CTD
PMID:1901333 PMID:12438370 PMID:15579454 PMID:22461696
RGD:8548784 RGD:8548789
NCBI chr 6:31,236,650...31,239,423
Ensembl chr 6:32,126,618...32,129,381
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all